Ultragenyx Pharmaceutical Inc

Chart & Performance

D1W1MN

P/E

—

P/S

4.44

EPS

—

Div Yield, %

—

Shrs. gr., 5y

9.86%

Rev. gr., 5y

40.12%

Revenues

560m

+29.01%

Net income

-569m

L-6.17%

CFO

-414m

L-12.77%

Earnings

Jul 30, 2025

Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

URL

https://www.ultragenyx.com/

IPO date

Jan 31, 2014

Employees

1,311

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	560,230 29.01%	434,249 19.52%	363,329 3.39%
Cost of revenue	774,593	693,658	734,109
Unusual Expense (Income)
NOPBT	(214,363)	(259,409)	(370,780)
NOPBT Margin
Operating Taxes	1,597	(1,825)	5,696
Tax Rate
NOPAT	(215,960)	(257,584)	(376,476)
Net income	(569,183) -6.17%	(606,639) -14.25%	(707,421) 55.81%
Dividends
Dividend yield
Proceeds from repurchase of equity	380,983	379,755	10,813
BB yield	-10.00%	-10.80%	-0.33%
Debt
Debt current	10,297	12,595	11,779
Long-term debt	10,297	73,743	51,407
Deferred revenue
Other long-term liabilities	866,948	874,530	880,259
Net debt	(589,431)	(690,772)	(988,047)
Cash flow
Cash from operating activities	(414,188)	(474,806)	(380,465)
CAPEX	(7,491)	(44,267)	(146,123)
Cash from investing activities	(17,768)	168,000	(291,652)
Cash from financing activities	399,241	388,142	501,208
FCF	(191,323)	(262,463)	(485,980)
Balance
Cash	610,025	577,209	896,732
Long term investments		199,901	154,501
Excess cash	582,014	755,398	1,033,067
Stockholders' equity	(3,950,395)	(3,386,932)	(2,787,525)
Invested Capital	5,089,937	4,580,045	4,051,871
ROIC
ROCE
EV
Common stock shares outstanding	90,538	73,544	69,914
Price	42.07 -12.02%	47.82 3.22%	46.33 -44.90%
Market cap	3,808,939 8.30%	3,516,867 8.57%	3,239,126 -43.18%
EV	3,226,508	2,826,095	2,251,079
EBITDA	(178,820)	(233,403)	(352,560)
EV/EBITDA
Interest	63,041	66,004	43,015
Interest/NOPBT